Phathom Pharmaceuticals, Inc. PHAT

PHAT Company Overview

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, with a primary emphasis on acid-related disorders. The company’s core mission is to address limitations of existing proton pump inhibitor (PPI) therapies by introducing differentiated acid-suppression medicines with faster onset and more consistent control. Phathom operates within the biopharmaceuticals and specialty therapeutics industry and primarily serves gastroenterologists, hospitals, and patients with chronic GI conditions.

Phathom was founded in 2018 and became a publicly traded company in 2019. Its strategy has centered on advancing vonoprazan, a potassium-competitive acid blocker (P-CAB) licensed from Takeda Pharmaceutical Company, for multiple U.S. indications. The company’s positioning is based on vonoprazan’s differentiated mechanism of action compared to traditional PPIs, offering rapid and sustained acid suppression. Over time, Phathom has evolved from a development-stage company into a commercial-stage organization following U.S. regulatory approvals.